ClinicalTrials.gg
CompletedNCT04468347Updated Sep 25, 2020Results posted

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer Disease and Mild Cognitive Impairment, sponsored by Avid Radiopharmaceuticals. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 5 years 9 months after the study started (first participant enrolled Oct 2014, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
10th of 22
89 · median 70
Started
2014
with 3 others
Phase 1
10 of 22
2 open now
Registered
20th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 10th largest by enrollment, is one of 4 that started in 2014, is one of 10 in phase 1, and was the 20th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.

Read the detailed description

The Australian Imaging Biomarkers and Lifestyle Study (AIBL) is a multicenter multidisciplinary study of Alzheimer's disease and aging funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Flagship Initiative, involving research centers in both Victoria and Western Australia. The goal of the A08 protocol was to further investigate the positron emission tomography (PET) imaging results with flortaucipir in patients across the AD spectrum from individuals with subjective memory complaints (SMC) to those with dementia, based on recruitment into the parent AIBL study.

03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet all inclusion criteria for the AIBL study protocol, with amyloid PET conducted or planned and MRI available
  • Subjects in the MCI and AD groups required to have a reliable caregiver capable of providing information about the subjects' symptoms

Exclusion criteria

Exclusion Criteria:

  • lifetime history of schizophrenia, schizoaffective disorder, or bipolar disorder
  • history of electroconvulsive therapy
  • MRI
  • claustrophobic or, otherwise, unable to tolerate the imaging procedure
  • current cardiovascular disease or clinically significant abnormalities on screening
  • history of additional risk factors for Torsades de Pointes
  • current clinically significant infectious disease, endocrine or metabolic disease, or pulmonary, renal, or hepatic impairment that the investigator believes would affect study participation
  • history of cancer (other than skin or in situ prostate cancer) within the previous 5 years
  • current drug or alcohol abuse/dependence
  • history of alcohol abuse/dependence with 2 years of the onset of the symptoms of dementia
  • females of who were not surgically sterile, not refraining from sexual activity, or not using reliable methods of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Alzheimer's disease (AD)

    Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Mild cognitive impairment (MCI)

    Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Subjective memory complainers (SMC)

    Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Cognitively normal (CN)

    Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • IV injection, 240 megabecquerel (MBq) (6.5 mCi)

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Flortaucipir PET Imaging (Quantitative)

    Flortaucipir PET cortical weighted average standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

  2. Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status

    Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with Advanced (τAD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (τAD+/τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.

    Time frame: baseline scan

  3. Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status

    Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with AD Pattern scans (Advanced \[τAD++\] and Moderate \[τAD+\] Scan Pattern) were combined vs. the Not AD pattern group (τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.

    Time frame: baseline scan

07

Results

Posted Sep 25, 2020

Participant flow

Enrollment occurred between Oct 2014 and Feb 2018 from the Australian Imaging, Biomarker \& Lifestyle Flagship Study of Ageing (AIBL)

Participant flow — Overall Study
MilestoneAlzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)
Started6114725
Baseline flortacuipir pet scan5114525
Completed4104121
Not completed2164
Withdrew: Withdrawal by subject0133
Withdrew: Lost to follow-up0011
Withdrew: Physician decision1020
Withdrew: Protocol violation1000

Outcome measures

PrimaryFlortaucipir PET Imaging (Quantitative)

Flortaucipir PET cortical weighted average standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Flortaucipir PET Imaging (Quantitative)
standardized uptake value ratio (SUVr)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Objectively ImpairedSubjective Memory Complainers (SMC)Cognitively Normal (CN)Non-objectively Compared
Flortaucipir PET Imaging (Quantitative)1.31 ± 0.0591.13 ± 0.0331.15 ± 0.0311.08 ± 0.0161.04 ± 0.0281.07 ± 0.015
Statistical analysis
  • Objectively Impaired vs Non-objectively Compared · ANOVA · p = <0.0001 · Mean difference (net): 0.16The two-way ANOVA included cognitive and amyloid status, and their interaction as fixed effects.
  • Objectively Impaired vs Subjective Memory Complainers (SMC) · ANOVA · p = 0.0005 · Mean difference (net): 0.14The two-way ANOVA included cognitive and amyloid status, and their interaction as fixed effects.
  • Subjective Memory Complainers (SMC) vs Cognitively Normal (CN) · ANOVA · p = 0.2161 · Mean difference (net): -0.04The two-way ANOVA included cognitive and amyloid status, and their interaction as fixed effects.
PrimaryNumber of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status

Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with Advanced (τAD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (τAD+/τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.

Time frame:
baseline scan
Reported as:
Count of participants · Participants
Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status
ParticipantsAlzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)
Amyloid Positive — Advanced AD Scan Pattern (τAD++)2390
Amyloid Positive — Not Advanced AD Pattern22114
Amyloid Negative — Advanced AD Scan Pattern (τAD++)1031
Amyloid Negative — Not Advanced AD Pattern062220
Statistical analysis
  • Alzheimer's Disease (AD) vs Mild Cognitive Impairment (MCI) vs Subjective Memory Complainers (SMC) vs Cognitively Normal (CN) · Cochran-Mantel-Haenszel · p = 0.1998
PrimaryNumber of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status

Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For this analysis, subjects with AD Pattern scans (Advanced \[τAD++\] and Moderate \[τAD+\] Scan Pattern) were combined vs. the Not AD pattern group (τAD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study.

Time frame:
baseline scan
Reported as:
Count of participants · Participants
Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status
ParticipantsAlzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)
Amyloid Positive — AD Pattern Scan (Advanced or Moderate)24110
Amyloid Positive — Not AD Pattern Scan2194
Amyloid Negative — AD Pattern Scan (Advanced or Moderate)1061
Amyloid Negative — Not AD Pattern Scan061920
Statistical analysis
  • Alzheimer's Disease (AD) vs Mild Cognitive Impairment (MCI) vs Subjective Memory Complainers (SMC) vs Cognitively Normal (CN) · Cochran-Mantel-Haenszel · p = 0.0646

Adverse events

Collected over End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alzheimer's Disease (AD)0/5 (0%)0/5 (0%)0/5 (0%)
Mild Cognitive Impairment (MCI)0/11 (0%)0/11 (0%)0/11 (0%)
Subjective Memory Complainers (SMC)0/45 (0%)0/45 (0%)1/45 (2.2%)
Cognitively Normal (CN)0/25 (0%)0/25 (0%)1/25 (4%)
Most frequent other events
Most frequent other events
EventAlzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)
dermatitis contactSkin and subcutaneous tissue disorders0/50/110/451/25
headacheNervous system disorders0/50/111/450/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
Mean76.2 ± 6.5374.3 ± 5.8277 ± 7.4372.9 ± 4.6775.4 ± 6.64
Sex: Female, Male
Sex: Female, Male(Participants)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
Female24261345
Male37191241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
Hispanic or Latino00000
Not Hispanic or Latino511452586
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White511442585
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
Australia511452586
Mini Mental Status Exam (MMSE)
Mini Mental Status Exam (MMSE)(units on a scale)Alzheimer's Disease (AD)Mild Cognitive Impairment (MCI)Subjective Memory Complainers (SMC)Cognitively Normal (CN)Total
Mean22.6 ± 3.2125.5 ± 2.8428 ± 1.6628.6 ± 0.9927.5 ± 2.35
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Feb 2018, 40 months.

Results were first posted in Sep 2020, 2 years 7 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 40 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2020
First posted
Jul 13, 2020
StartActual
Oct 2014
Primary completionActual
Feb 2018
CompletionActual
Feb 2018
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04468347
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Oct 2014
Primary completion
Feb 2018
Completion
Feb 2018
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Chief Medical Officer
study director · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion